Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2872-2879

  Gupta, Soumi ^a   Vingerhoets, Johan ^b   Fransen, Signe ^a   Tambuyzer, Lotke ^b   Azijn, Hilde ^b   Frantzell, Arne ^a   Paredes, Roger ^c   Coakley, Eoin ^a   Nijs, Steven ^b   Clotet, Bonaventura ^c   Petropoulos, Christos J ^a   Schapiro, Jonathan ^d   Huang, Wei ^a   Picchio, Gaston ^e  

^a MONOGRAM BIOSCIENCES   (United States)

^b TIBOTEC BVBA   (Belgium)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d SHEBA MEDICAL CENTER   (Israel)

^e Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; ENHANCED GREEN FLUORESCENT PROTEIN; ETRAVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CONNECTION DOMAIN MUTATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DOSE REGIMEN; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; RETROSPECTIVE STUDY; SITE DIRECTED MUTAGENESIS; TREATMENT RESPONSE; VIRUS REPLICATION; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHENOTYPE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79956301190     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01695-10     Document Type: Article

References (38)

1. Andries, K., et al. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
2. Benhamida, J., E. Coakley, N. T. Parkin, and C. Chappey. 2008. Increased phenotypic susceptibility to etravirine in HIV-1 with NRTI resistance. Antivir. Ther. 13(Suppl. 3):A24. (Abstract.)
3. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Stat. Methodol. 57:289-300.
4. Brehm, J. H., et al. 2007. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J. Virol. 81:7852-7859. (Pubitemid 47101471)
5. Brown, A. J., et al. 2000. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J. Virol. 74:10269-10273.
6. Das, K., et al. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
7. Delviks-Frankenberry, K. A., G. N. Nikolenko, R. Barr, and V. K. Pathak. 2007. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J. Virol. 81:6837-6845.
8. Figueiredo, A., et al. 2007. The E399G mutation in the connection domain of the HIV-1 reverse transcriptase potentiates resistance to efavirenz, abstr. MOPEA060. Abstr. 4th IAS Conf. HIV Pathol., Treat. Prev.
9. Götte, M. 2007. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. PLoS Med. 4:1858-1861.
10. Gupta, S., et al. 2007. Novel electrophoretic-tag-based in vitro assay to quantify dimerization of P66 and P51 subunits of HIV-1 reverse transcriptase (RT). Antivir. Ther. 12:S156. (Abstract.)
11. Gupta, S., et al. 2010. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 54:1973-1980.
12. Hachiya, A., et al. 2008. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 82:3261-3270. (Pubitemid 351429905)
13. Hachiya, A., et al. 2009. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. Antiviral Res. 82:115-121.
14. Haddad, M., E. Stawiski, J. Benhamida, and E. Coakley. 2010. Improved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype, abstr 574. Abstr. 17th Conf. Retrovir. Opportunistic Infect.
15. Harrigan, P. R., et al. 2002. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J. Virol. 76:6836-6840. (Pubitemid 34633550)
16. Hertogs, K., et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
17. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
18. Jacobo-Molina, A., et al. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. U. S. A. 90:6320-6324.
19. Johnson, V. A., et al. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 17:138-145.
20. Katlama, C., et al. 2009. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 23:2289-2300.
21. Kemp, S. D., et al. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J. Virol. 72:5093-5098. (Pubitemid 28215690)
22. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
23. Lazzarin, A., et al. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48. (Pubitemid 47017467)
24. Madruga, J. V., et al. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:29-38. (Pubitemid 47017466)
25. Nikolenko, G. N., et al. 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc. Natl. Acad. Sci. U. S. A. 104:317-322.
26. Nikolenko, G. N., K. A. Delviks-Frankenberry, and V. K. Pathak. 2010. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 84:5238-5249.
27. Paredes, R., et al. 2009. Mutation A376S in the RT connection domain is associated with an increased risk of VF to nevirapine-based therapy in NNRTI-naïve HIV-infected subjects: the EuroSIDA study, abstr 464. Abstr. 16th Conf. Retrovir. Opportunistic Infect.
28. Pauwels, R., et al. 1998. Comprehensive HIV drug resistance monitoring using rapid, high throughput phenotypic and genotypic assays with correlative data analysis. Antivir. Ther. 3(Suppl. 1):35-36. (Abstract.)
29. Petropoulos, C. J., et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
30. Picchio, G., J. Vingerhoets, N. Parkin, H. Azijn, and M. P. de Béthune. 2008. Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR). Antivir. Ther. 13(Suppl. 3):A25. (Abstract.)
31. Poveda, E., et al. 2008. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 22:2395-2398.
32. Sarafianos, S. G., et al. 1999. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. 6:R137-R146.
33. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. Biotechniques 8:404-407.
34. Vingerhoets, J., et al. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro experiments. J. Virol. 79:12773-12782. (Pubitemid 41433197)
35. Vingerhoets, J., et al. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies AIDS 24:503-514.
36. Wang, J., S. J. Smerdon, J. Jäger, L. A. Kohlstaedt, P. A. Rice, J. M. Friedman, and T. A. Steitz. 1994. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. U. S. A. 91:7242-7246.
37. Yap, S. H., et al. 2007. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 4:1887-1900.
38. Zhang, Z., et al. 2007. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51:429-437.